Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV
Accurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability between assays exists. We compared three methods to quantify HDV RNA levels in untreated and bulevirtide (BLV)-treated patients with CHD. Frozen plasma from untreat...
Saved in:
| Published in | JHEP reports Vol. 7; no. 3; p. 101299 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.03.2025
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Accurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability between assays exists. We compared three methods to quantify HDV RNA levels in untreated and bulevirtide (BLV)-treated patients with CHD.
Frozen plasma from untreated and BLV-treated patients with CHD were tested in a single-center retrospective study using three different assays: Robogene 2.0 HDV RNA Quantification Kit 2.0 (Roboscreen GmbH; limit of detection [LOD] 6 IU/ml on 7500 Fast Real-Time PCR System [Applied Biosystem]), EurobioPlex HDV PCR quantitative kit (Eurobio Scientific; LOD 100 IU/m) on CFX96™ real-time PCR detection system [Bio-Rad]), and AltoStar HDV RT-PCR RUO Kit 1.5 (Altona Diagnostics; estimated LOD <10 IU/ml) on the AltoStar®AM16.
Overall, 431 plasma samples from 130 patients with CHD (69 untreated and 61 BLV-treated) were studied. Compared with Robogene 2.0, EurobioPlex reported higher HDV RNA levels (3.78 [0.70–7.99] vs. 4.69 [2.00–8.19] log IU/ml, p <0.0001), with viremia higher than >0.5 log in 160 (69%). Likewise, HDV RNA levels were higher with AltoStar than with Robogene 2.0 (3.32 [0.70–7.37] vs. 3.91 [0.19–7.54] log IU/ml, p <0.0001), with AltoStar reporting HDV RNA levels >0.5 log in 127 (52%). Although virological response rates (≥2 log decline vs. baseline) at Weeks 24 (Robogene 2.0 vs. EurobioPlex and AltoStar) and 48 (Robogene 2.0 vs. AltoStar) were similar across assays, rates of HDV RNA undetectability significantly differed between the three assays at Weeks 24 and 72 (p = 0.003 and p = 0.02, respectively).
HDV RNA levels quantified by EurobioPlex and AltoStar were 1 and 0.5 logs higher than those quantified by Robogene 2.0, respectively. HDV RNA undetectability rates during BLV treatment were assay-dependent.
Management and diagnosis of chronic hepatitis delta (CHD) require standardized tests for HDV RNA quantification. Quantification of HDV RNA is significantly influenced by the quantification method, with EurobioPlex detecting approximatively 1 log and AltoStar 0.5 log IU/ml more than Robogene 2.0, respectively. The HDV RNA undetectability rates during BLV monotherapy significantly differed among assays. These findings are of clinical relevance as patients who achieve negative viremia during BLV monotherapy might be entitled to stop therapy successfully.
[Display omitted]
•Management of chronic hepatitis delta requires standardized tests for HDV RNA.•EurobioPlex reports 1 log IU/ml more and AltoStar 0.5 log IU/ml more HDV RNA than Robogene 2.0.•Despite similar virological response rates, HDV RNA undetectability rates were significantly higher with Robogene 2.0 than AltoStar.•These findings are important, as patients who achieve negative viremia during BLV monotherapy might be able to safely stop therapy. |
|---|---|
| AbstractList | Background & AimsAccurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability between assays exists. We compared three methods to quantify HDV RNA levels in untreated and bulevirtide (BLV)-treated patients with CHD. MethodsFrozen plasma from untreated and BLV-treated patients with CHD were tested in a single-center retrospective study using three different assays: Robogene 2.0 HDV RNA Quantification Kit 2.0 (Roboscreen GmbH; limit of detection [LOD] 6 IU/ml on 7500 Fast Real-Time PCR System [Applied Biosystem]), EurobioPlex HDV PCR quantitative kit (Eurobio Scientific; LOD 100 IU/m) on CFX96™ real-time PCR detection system [Bio-Rad]), and AltoStar HDV RT-PCR RUO Kit 1.5 (Altona Diagnostics; estimated LOD <10 IU/ml) on the AltoStar®AM16. ResultsOverall, 431 plasma samples from 130 patients with CHD (69 untreated and 61 BLV-treated) were studied. Compared with Robogene 2.0, EurobioPlex reported higher HDV RNA levels (3.78 [0.70–7.99] vs. 4.69 [2.00–8.19] log IU/ml, p <0.0001), with viremia higher than >0.5 log in 160 (69%). Likewise, HDV RNA levels were higher with AltoStar than with Robogene 2.0 (3.32 [0.70–7.37] vs. 3.91 [0.19–7.54] log IU/ml, p <0.0001), with AltoStar reporting HDV RNA levels >0.5 log in 127 (52%). Although virological response rates (≥2 log decline vs. baseline) at Weeks 24 (Robogene 2.0 vs. EurobioPlex and AltoStar) and 48 (Robogene 2.0 vs. AltoStar) were similar across assays, rates of HDV RNA undetectability significantly differed between the three assays at Weeks 24 and 72 ( p = 0.003 and p = 0.02, respectively). ConclusionsHDV RNA levels quantified by EurobioPlex and AltoStar were 1 and 0.5 logs higher than those quantified by Robogene 2.0, respectively. HDV RNA undetectability rates during BLV treatment were assay-dependent. Impact and implications:Management and diagnosis of chronic hepatitis delta (CHD) require standardized tests for HDV RNA quantification. Quantification of HDV RNA is significantly influenced by the quantification method, with EurobioPlex detecting approximatively 1 log and AltoStar 0.5 log IU/ml more than Robogene 2.0, respectively. The HDV RNA undetectability rates during BLV monotherapy significantly differed among assays. These findings are of clinical relevance as patients who achieve negative viremia during BLV monotherapy might be entitled to stop therapy successfully. Accurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability between assays exists. We compared three methods to quantify HDV RNA levels in untreated and bulevirtide (BLV)-treated patients with CHD.Background & AimsAccurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability between assays exists. We compared three methods to quantify HDV RNA levels in untreated and bulevirtide (BLV)-treated patients with CHD.Frozen plasma from untreated and BLV-treated patients with CHD were tested in a single-center retrospective study using three different assays: Robogene 2.0 HDV RNA Quantification Kit 2.0 (Roboscreen GmbH; limit of detection [LOD] 6 IU/ml on 7500 Fast Real-Time PCR System [Applied Biosystem]), EurobioPlex HDV PCR quantitative kit (Eurobio Scientific; LOD 100 IU/m) on CFX96™ real-time PCR detection system [Bio-Rad]), and AltoStar HDV RT-PCR RUO Kit 1.5 (Altona Diagnostics; estimated LOD <10 IU/ml) on the AltoStar®AM16.MethodsFrozen plasma from untreated and BLV-treated patients with CHD were tested in a single-center retrospective study using three different assays: Robogene 2.0 HDV RNA Quantification Kit 2.0 (Roboscreen GmbH; limit of detection [LOD] 6 IU/ml on 7500 Fast Real-Time PCR System [Applied Biosystem]), EurobioPlex HDV PCR quantitative kit (Eurobio Scientific; LOD 100 IU/m) on CFX96™ real-time PCR detection system [Bio-Rad]), and AltoStar HDV RT-PCR RUO Kit 1.5 (Altona Diagnostics; estimated LOD <10 IU/ml) on the AltoStar®AM16.Overall, 431 plasma samples from 130 patients with CHD (69 untreated and 61 BLV-treated) were studied. Compared with Robogene 2.0, EurobioPlex reported higher HDV RNA levels (3.78 [0.70-7.99] vs. 4.69 [2.00-8.19] log IU/ml, p <0.0001), with viremia higher than >0.5 log in 160 (69%). Likewise, HDV RNA levels were higher with AltoStar than with Robogene 2.0 (3.32 [0.70-7.37] vs. 3.91 [0.19-7.54] log IU/ml, p <0.0001), with AltoStar reporting HDV RNA levels >0.5 log in 127 (52%). Although virological response rates (≥2 log decline vs. baseline) at Weeks 24 (Robogene 2.0 vs. EurobioPlex and AltoStar) and 48 (Robogene 2.0 vs. AltoStar) were similar across assays, rates of HDV RNA undetectability significantly differed between the three assays at Weeks 24 and 72 (p = 0.003 and p = 0.02, respectively).ResultsOverall, 431 plasma samples from 130 patients with CHD (69 untreated and 61 BLV-treated) were studied. Compared with Robogene 2.0, EurobioPlex reported higher HDV RNA levels (3.78 [0.70-7.99] vs. 4.69 [2.00-8.19] log IU/ml, p <0.0001), with viremia higher than >0.5 log in 160 (69%). Likewise, HDV RNA levels were higher with AltoStar than with Robogene 2.0 (3.32 [0.70-7.37] vs. 3.91 [0.19-7.54] log IU/ml, p <0.0001), with AltoStar reporting HDV RNA levels >0.5 log in 127 (52%). Although virological response rates (≥2 log decline vs. baseline) at Weeks 24 (Robogene 2.0 vs. EurobioPlex and AltoStar) and 48 (Robogene 2.0 vs. AltoStar) were similar across assays, rates of HDV RNA undetectability significantly differed between the three assays at Weeks 24 and 72 (p = 0.003 and p = 0.02, respectively).HDV RNA levels quantified by EurobioPlex and AltoStar were 1 and 0.5 logs higher than those quantified by Robogene 2.0, respectively. HDV RNA undetectability rates during BLV treatment were assay-dependent.ConclusionsHDV RNA levels quantified by EurobioPlex and AltoStar were 1 and 0.5 logs higher than those quantified by Robogene 2.0, respectively. HDV RNA undetectability rates during BLV treatment were assay-dependent.Management and diagnosis of chronic hepatitis delta (CHD) require standardized tests for HDV RNA quantification. Quantification of HDV RNA is significantly influenced by the quantification method, with EurobioPlex detecting approximatively 1 log and AltoStar 0.5 log IU/ml more than Robogene 2.0, respectively. The HDV RNA undetectability rates during BLV monotherapy significantly differed among assays. These findings are of clinical relevance as patients who achieve negative viremia during BLV monotherapy might be entitled to stop therapy successfully.Impact and implicationsManagement and diagnosis of chronic hepatitis delta (CHD) require standardized tests for HDV RNA quantification. Quantification of HDV RNA is significantly influenced by the quantification method, with EurobioPlex detecting approximatively 1 log and AltoStar 0.5 log IU/ml more than Robogene 2.0, respectively. The HDV RNA undetectability rates during BLV monotherapy significantly differed among assays. These findings are of clinical relevance as patients who achieve negative viremia during BLV monotherapy might be entitled to stop therapy successfully. Accurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability between assays exists. We compared three methods to quantify HDV RNA levels in untreated and bulevirtide (BLV)-treated patients with CHD. Frozen plasma from untreated and BLV-treated patients with CHD were tested in a single-center retrospective study using three different assays: Robogene 2.0 HDV RNA Quantification Kit 2.0 (Roboscreen GmbH; limit of detection [LOD] 6 IU/ml on 7500 Fast Real-Time PCR System [Applied Biosystem]), EurobioPlex HDV PCR quantitative kit (Eurobio Scientific; LOD 100 IU/m) on CFX96™ real-time PCR detection system [Bio-Rad]), and AltoStar HDV RT-PCR RUO Kit 1.5 (Altona Diagnostics; estimated LOD <10 IU/ml) on the AltoStar®AM16. Overall, 431 plasma samples from 130 patients with CHD (69 untreated and 61 BLV-treated) were studied. Compared with Robogene 2.0, EurobioPlex reported higher HDV RNA levels (3.78 [0.70-7.99] . 4.69 [2.00-8.19] log IU/ml, <0.0001), with viremia higher than >0.5 log in 160 (69%). Likewise, HDV RNA levels were higher with AltoStar than with Robogene 2.0 (3.32 [0.70-7.37] . 3.91 [0.19-7.54] log IU/ml, <0.0001), with AltoStar reporting HDV RNA levels >0.5 log in 127 (52%). Although virological response rates (≥2 log decline baseline) at Weeks 24 (Robogene 2.0 EurobioPlex and AltoStar) and 48 (Robogene 2.0 AltoStar) were similar across assays, rates of HDV RNA undetectability significantly differed between the three assays at Weeks 24 and 72 ( = 0.003 and = 0.02, respectively). HDV RNA levels quantified by EurobioPlex and AltoStar were 1 and 0.5 logs higher than those quantified by Robogene 2.0, respectively. HDV RNA undetectability rates during BLV treatment were assay-dependent. Management and diagnosis of chronic hepatitis delta (CHD) require standardized tests for HDV RNA quantification. Quantification of HDV RNA is significantly influenced by the quantification method, with EurobioPlex detecting approximatively 1 log and AltoStar 0.5 log IU/ml more than Robogene 2.0, respectively. The HDV RNA undetectability rates during BLV monotherapy significantly differed among assays. These findings are of clinical relevance as patients who achieve negative viremia during BLV monotherapy might be entitled to stop therapy successfully. Background & Aims: Accurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability between assays exists. We compared three methods to quantify HDV RNA levels in untreated and bulevirtide (BLV)-treated patients with CHD. Methods: Frozen plasma from untreated and BLV-treated patients with CHD were tested in a single-center retrospective study using three different assays: Robogene 2.0 HDV RNA Quantification Kit 2.0 (Roboscreen GmbH; limit of detection [LOD] 6 IU/ml on 7500 Fast Real-Time PCR System [Applied Biosystem]), EurobioPlex HDV PCR quantitative kit (Eurobio Scientific; LOD 100 IU/m) on CFX96™ real-time PCR detection system [Bio-Rad]), and AltoStar HDV RT-PCR RUO Kit 1.5 (Altona Diagnostics; estimated LOD <10 IU/ml) on the AltoStar®AM16. Results: Overall, 431 plasma samples from 130 patients with CHD (69 untreated and 61 BLV-treated) were studied. Compared with Robogene 2.0, EurobioPlex reported higher HDV RNA levels (3.78 [0.70–7.99] vs. 4.69 [2.00–8.19] log IU/ml, p <0.0001), with viremia higher than >0.5 log in 160 (69%). Likewise, HDV RNA levels were higher with AltoStar than with Robogene 2.0 (3.32 [0.70–7.37] vs. 3.91 [0.19–7.54] log IU/ml, p <0.0001), with AltoStar reporting HDV RNA levels >0.5 log in 127 (52%). Although virological response rates (≥2 log decline vs. baseline) at Weeks 24 (Robogene 2.0 vs. EurobioPlex and AltoStar) and 48 (Robogene 2.0 vs. AltoStar) were similar across assays, rates of HDV RNA undetectability significantly differed between the three assays at Weeks 24 and 72 (p = 0.003 and p = 0.02, respectively). Conclusions: HDV RNA levels quantified by EurobioPlex and AltoStar were 1 and 0.5 logs higher than those quantified by Robogene 2.0, respectively. HDV RNA undetectability rates during BLV treatment were assay-dependent. Impact and implications:: Management and diagnosis of chronic hepatitis delta (CHD) require standardized tests for HDV RNA quantification. Quantification of HDV RNA is significantly influenced by the quantification method, with EurobioPlex detecting approximatively 1 log and AltoStar 0.5 log IU/ml more than Robogene 2.0, respectively. The HDV RNA undetectability rates during BLV monotherapy significantly differed among assays. These findings are of clinical relevance as patients who achieve negative viremia during BLV monotherapy might be entitled to stop therapy successfully. Accurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability between assays exists. We compared three methods to quantify HDV RNA levels in untreated and bulevirtide (BLV)-treated patients with CHD. Frozen plasma from untreated and BLV-treated patients with CHD were tested in a single-center retrospective study using three different assays: Robogene 2.0 HDV RNA Quantification Kit 2.0 (Roboscreen GmbH; limit of detection [LOD] 6 IU/ml on 7500 Fast Real-Time PCR System [Applied Biosystem]), EurobioPlex HDV PCR quantitative kit (Eurobio Scientific; LOD 100 IU/m) on CFX96™ real-time PCR detection system [Bio-Rad]), and AltoStar HDV RT-PCR RUO Kit 1.5 (Altona Diagnostics; estimated LOD <10 IU/ml) on the AltoStar®AM16. Overall, 431 plasma samples from 130 patients with CHD (69 untreated and 61 BLV-treated) were studied. Compared with Robogene 2.0, EurobioPlex reported higher HDV RNA levels (3.78 [0.70–7.99] vs. 4.69 [2.00–8.19] log IU/ml, p <0.0001), with viremia higher than >0.5 log in 160 (69%). Likewise, HDV RNA levels were higher with AltoStar than with Robogene 2.0 (3.32 [0.70–7.37] vs. 3.91 [0.19–7.54] log IU/ml, p <0.0001), with AltoStar reporting HDV RNA levels >0.5 log in 127 (52%). Although virological response rates (≥2 log decline vs. baseline) at Weeks 24 (Robogene 2.0 vs. EurobioPlex and AltoStar) and 48 (Robogene 2.0 vs. AltoStar) were similar across assays, rates of HDV RNA undetectability significantly differed between the three assays at Weeks 24 and 72 (p = 0.003 and p = 0.02, respectively). HDV RNA levels quantified by EurobioPlex and AltoStar were 1 and 0.5 logs higher than those quantified by Robogene 2.0, respectively. HDV RNA undetectability rates during BLV treatment were assay-dependent. Management and diagnosis of chronic hepatitis delta (CHD) require standardized tests for HDV RNA quantification. Quantification of HDV RNA is significantly influenced by the quantification method, with EurobioPlex detecting approximatively 1 log and AltoStar 0.5 log IU/ml more than Robogene 2.0, respectively. The HDV RNA undetectability rates during BLV monotherapy significantly differed among assays. These findings are of clinical relevance as patients who achieve negative viremia during BLV monotherapy might be entitled to stop therapy successfully. [Display omitted] •Management of chronic hepatitis delta requires standardized tests for HDV RNA.•EurobioPlex reports 1 log IU/ml more and AltoStar 0.5 log IU/ml more HDV RNA than Robogene 2.0.•Despite similar virological response rates, HDV RNA undetectability rates were significantly higher with Robogene 2.0 than AltoStar.•These findings are important, as patients who achieve negative viremia during BLV monotherapy might be able to safely stop therapy. Image 1 • Management of chronic hepatitis delta requires standardized tests for HDV RNA. • EurobioPlex reports 1 log IU/ml more and AltoStar 0.5 log IU/ml more HDV RNA than Robogene 2.0. • Despite similar virological response rates, HDV RNA undetectability rates were significantly higher with Robogene 2.0 than AltoStar. • These findings are important, as patients who achieve negative viremia during BLV monotherapy might be able to safely stop therapy. |
| ArticleNumber | 101299 |
| Author | Facchetti, Floriana Monico, Sara Borghi, Marta Callegaro, Annapaola Sambarino, Dana Anolli, Maria Paola Degasperi, Elisabetta Soffredini, Roberta Lampertico, Pietro Uceda Renteria, Sara Perbellini, Riccardo |
| Author_xml | – sequence: 1 givenname: Maria Paola orcidid: 0000-0001-6901-5575 surname: Anolli fullname: Anolli, Maria Paola organization: Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 2 givenname: Sara orcidid: 0000-0002-2027-8478 surname: Uceda Renteria fullname: Uceda Renteria, Sara organization: Microbiology and Virology Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 3 givenname: Elisabetta orcidid: 0000-0002-9899-4669 surname: Degasperi fullname: Degasperi, Elisabetta organization: Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 4 givenname: Floriana orcidid: 0000-0001-5252-4744 surname: Facchetti fullname: Facchetti, Floriana organization: Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 5 givenname: Dana surname: Sambarino fullname: Sambarino, Dana organization: Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 6 givenname: Marta surname: Borghi fullname: Borghi, Marta organization: Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 7 givenname: Riccardo orcidid: 0000-0002-4412-1256 surname: Perbellini fullname: Perbellini, Riccardo organization: Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 8 givenname: Roberta surname: Soffredini fullname: Soffredini, Roberta organization: Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 9 givenname: Sara surname: Monico fullname: Monico, Sara organization: Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 10 givenname: Annapaola surname: Callegaro fullname: Callegaro, Annapaola organization: Microbiology and Virology Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 11 givenname: Pietro orcidid: 0000-0002-1026-7476 surname: Lampertico fullname: Lampertico, Pietro email: pietro.lampertico@unimi.it organization: Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40051411$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkttu1DAQhiNUREvpEyChXHKziw9xYgtBVS2FVqpA4nRrOfZk1yGxUzvZqm-P022rFgn1yqf5vxnP_C-zPecdZNlrjJYY4fJdu2w3MIQlQaSYb4gQz7IDwrhYMMbE3oP9fnYUY4sQIpUokvZFtl8gxHCB8UHWrnw_qGDdOu9h3HgT88aHfOhU7FV-9ul3_v3rSX45KTfaxmo1Wu9y6_J66mBrw2gNLMYAagSTK2fyyd2dhhQLboz5lR03M-lV9rxRXYSj2_Uw-_X59OfqbHHx7cv56uRioRmn40IgokRhBKtLQ4hQNae0VJpj1QhU8aqoKs6YwaWpiloQ4KjCgta00hUjqhT0MDvfcY1XrRyC7VW4ll5ZeXPhw1qqVLjuQJKyMhqVZYMKWojGKAoco4YLqhjXJSTW8Y41THUPRqcPBdU9gj5-cXYj134rMeacFogmwttbQvCXE8RR9jZq6DrlwE9RUlwVnCBG5sLfPEx2n-VuWimA7gJ08DEGaO5DMJKzLWQrb2whZ1vInS2S6sNOBanpWwtBRp0mo8HYAHpMXbFP6D_-o9eddckL3R-4htj6Kbg0T4llJBLJH7PxZt-RVDdNHUiA9_8HPJn-L5Kw6Ns |
| Cites_doi | 10.1097/HEP.0000000000000584 10.1093/infdis/jiz633 10.1016/j.jhep.2017.03.021 10.1016/j.jhep.2020.04.008 10.1136/gutjnl-2020-323888 10.1371/journal.pone.0092062 10.1016/j.cgh.2015.05.029 10.1002/hep.28772 10.1016/j.jhep.2019.11.003 10.1002/hep.31214 10.1016/j.jhep.2018.12.022 10.1056/NEJMoa2314134 10.1016/S0016-5085(99)70563-9 10.1016/S1473-3099(18)30663-7 10.1056/NEJMoa2213429 10.1016/j.jhep.2022.12.023 10.1093/infdis/155.5.931 10.1016/j.dld.2024.01.026 10.1016/j.jcv.2021.104932 10.3851/IMP3281 10.1002/hep.27102 10.1016/S0168-8278(23)00520-2 10.1111/liv.15795 |
| ContentType | Journal Article |
| Copyright | 2024 The Authors The Authors 2024 The Authors. 2024 The Authors 2024 |
| Copyright_xml | – notice: 2024 The Authors – notice: The Authors – notice: 2024 The Authors. – notice: 2024 The Authors 2024 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.jhepr.2024.101299 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2589-5559 |
| EndPage | 101299 |
| ExternalDocumentID | oai_doaj_org_article_267dc066f04349fda3e810f893a58c6e PMC11883403 40051411 10_1016_j_jhepr_2024_101299 S2589555924003033 1_s2_0_S2589555924003033 |
| Genre | Journal Article |
| GroupedDBID | .1- .FO 0R~ 1P~ 53G AAEDW AALRI AAXUO AAYWO ACLIJ ACVFH ADCNI ADVLN AEUPX AEXQZ AFJKZ AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS FDB GROUPED_DOAJ M41 M~E OK1 ROL RPM SSZ Z5R 6I. AAFTH AAYXX CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c583t-902a94d95b6d229ab8336ac81af90787477855d16d74b92e807193b37c752a693 |
| IEDL.DBID | DOA |
| ISSN | 2589-5559 |
| IngestDate | Wed Aug 27 01:20:51 EDT 2025 Thu Aug 21 18:33:34 EDT 2025 Fri Jul 11 16:17:00 EDT 2025 Mon Jul 21 05:59:27 EDT 2025 Tue Jul 01 05:27:52 EDT 2025 Sat Mar 22 15:53:39 EDT 2025 Thu Apr 03 20:56:42 EDT 2025 Tue Aug 26 20:18:34 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Antiviral therapy Chronic hepatitis delta Robogene EurobioPlex HDV RNA HDV AltoStar Bulevirtide PCR Nucleic acid |
| Language | English |
| License | This is an open access article under the CC BY license. 2024 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c583t-902a94d95b6d229ab8336ac81af90787477855d16d74b92e807193b37c752a693 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-2027-8478 0000-0001-6901-5575 0000-0002-4412-1256 0000-0001-5252-4744 0000-0002-9899-4669 0000-0002-1026-7476 |
| OpenAccessLink | https://doaj.org/article/267dc066f04349fda3e810f893a58c6e |
| PMID | 40051411 |
| PQID | 3174820529 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_267dc066f04349fda3e810f893a58c6e pubmedcentral_primary_oai_pubmedcentral_nih_gov_11883403 proquest_miscellaneous_3174820529 pubmed_primary_40051411 crossref_primary_10_1016_j_jhepr_2024_101299 elsevier_sciencedirect_doi_10_1016_j_jhepr_2024_101299 elsevier_clinicalkeyesjournals_1_s2_0_S2589555924003033 elsevier_clinicalkey_doi_10_1016_j_jhepr_2024_101299 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2025-03-01 |
| PublicationDateYYYYMMDD | 2025-03-01 |
| PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | JHEP reports |
| PublicationTitleAlternate | JHEP Rep |
| PublicationYear | 2025 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Jachs, Panzer, Hartl (bib26) 2023; 5 Wedemeyer, Yurdaydin, Hardtke (bib5) 2019; 19 Fattovich, Boscaro, Noventa (bib3) 1987; 155 Pflüger, Nörz, Volz (bib17) 2021; 3 Wedemeyer, Aleman, Brunetto (bib20) 2023; 389 Urban, Neumann-Haefelin, Lampertico (bib18) 2021; 70 Anolli, Uceda Renteria, Degasperi (bib21) 2024; 44 Anolli, Degasperi, Allweiss (bib25) 2023 Wedemeyer, Leus, Battersby (bib15) 2025; 81 Romeo, Foglieni, Casazza (bib8) 2014; 9 Caviglia, Colombatto, Coco (bib28) 2024; 56 Stockdale, Kreuels, Henrion (bib1) 2020; 73 Yurdaydin, Abbas, Buti (bib12) 2019; 70 De Lédinghen, Hermabessière, Metivier (bib24) 2022; 76 Gerber, Huault, Delagarde (bib19) 2023; 78 De Lédinghen, Bardou-Jacquet, Metivier (bib23) 2023; 78 Heidrich, Yurdaydın, Kabaçam (bib27) 2014; 60 Stelzl, Ciesek, Cornberg (bib13) 2021; 142 (bib6) 2017; 67 Le Gal, Brichler, Sahli (bib22) 2016; 64 Keskin, Wedemeyer, Tüzün (bib9) 2015; 13 Rosina, Conoscitore, Cuppone (bib4) 1999; 117 Bremer, Anastasiou, Ciesek (bib14) 2019; 24 Chudy, Hanschmann, Bozdayi (bib16) 2013 Kamal, Westman, Falconer (bib10) 2020; 72 bib7 Miao, Zhang, Ou (bib2) 2020; 221 Cornberg, Lok, Terrault (bib11) 2020; 72 Asselah, Chulanov, Lampertico (bib29) 2024; 391 Anolli (10.1016/j.jhepr.2024.101299_bib21) 2024; 44 Wedemeyer (10.1016/j.jhepr.2024.101299_bib20) 2023; 389 Kamal (10.1016/j.jhepr.2024.101299_bib10) 2020; 72 Pflüger (10.1016/j.jhepr.2024.101299_bib17) 2021; 3 Anolli (10.1016/j.jhepr.2024.101299_bib25) 2023 (10.1016/j.jhepr.2024.101299_bib6) 2017; 67 De Lédinghen (10.1016/j.jhepr.2024.101299_bib23) 2023; 78 Wedemeyer (10.1016/j.jhepr.2024.101299_bib15) 2025; 81 Caviglia (10.1016/j.jhepr.2024.101299_bib28) 2024; 56 Heidrich (10.1016/j.jhepr.2024.101299_bib27) 2014; 60 Stelzl (10.1016/j.jhepr.2024.101299_bib13) 2021; 142 Asselah (10.1016/j.jhepr.2024.101299_bib29) 2024; 391 Rosina (10.1016/j.jhepr.2024.101299_bib4) 1999; 117 Cornberg (10.1016/j.jhepr.2024.101299_bib11) 2020; 72 De Lédinghen (10.1016/j.jhepr.2024.101299_bib24) 2022; 76 Bremer (10.1016/j.jhepr.2024.101299_bib14) 2019; 24 Le Gal (10.1016/j.jhepr.2024.101299_bib22) 2016; 64 Wedemeyer (10.1016/j.jhepr.2024.101299_bib5) 2019; 19 Yurdaydin (10.1016/j.jhepr.2024.101299_bib12) 2019; 70 Jachs (10.1016/j.jhepr.2024.101299_bib26) 2023; 5 Chudy (10.1016/j.jhepr.2024.101299_bib16) 2013 Gerber (10.1016/j.jhepr.2024.101299_bib19) 2023; 78 Miao (10.1016/j.jhepr.2024.101299_bib2) 2020; 221 Keskin (10.1016/j.jhepr.2024.101299_bib9) 2015; 13 Fattovich (10.1016/j.jhepr.2024.101299_bib3) 1987; 155 Romeo (10.1016/j.jhepr.2024.101299_bib8) 2014; 9 Stockdale (10.1016/j.jhepr.2024.101299_bib1) 2020; 73 Urban (10.1016/j.jhepr.2024.101299_bib18) 2021; 70 |
| References_xml | – volume: 391 start-page: 133 year: 2024 end-page: 143 ident: bib29 article-title: Bulevirtide combined with pegylated interferon for chronic hepatitis D publication-title: N Engl J Med – volume: 155 start-page: 931 year: 1987 end-page: 935 ident: bib3 article-title: Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B publication-title: J Infect Dis – volume: 81 start-page: 637 year: 2025 end-page: 650 ident: bib15 article-title: HDV RNA assays: performance characteristic, clinical utility, and challenges publication-title: Hepatology – volume: 3 year: 2021 ident: bib17 article-title: Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system publication-title: JHEP Rep – volume: 76 start-page: S26 year: 2022 end-page: S27 ident: bib24 article-title: Bulevirtide, with or without PEG-Interferon, in HDV infected patients in a real-life setting. Two years results from the French multicenter early access program publication-title: Hepatology – volume: 24 start-page: 117 year: 2019 end-page: 123 ident: bib14 article-title: Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation publication-title: Antivir Ther – volume: 72 start-page: 1177 year: 2020 end-page: 1190 ident: bib10 article-title: Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes publication-title: Hepatology – ident: bib7 article-title: EASL recommendations on treatment of hepatitis C – volume: 221 start-page: 1677 year: 2020 end-page: 1687 ident: bib2 article-title: Estimating the global prevalence, disease progression, and clinical outcome of Hepatitis Delta Virus infection publication-title: J Infect Dis – volume: 389 start-page: 22 year: 2023 end-page: 32 ident: bib20 article-title: A phase 3, randomized trial of bulevirtide in chronic hepatitis D publication-title: N Engl J Med – volume: 142 year: 2021 ident: bib13 article-title: Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: a European multicenter study publication-title: J Clin Virol – volume: 44 start-page: 831 year: 2024 end-page: 837 ident: bib21 article-title: Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods publication-title: Liver Int – volume: 117 start-page: 161 year: 1999 end-page: 166 ident: bib4 article-title: Changing pattern of chronic hepatitis D in Southern Europe publication-title: Gastroenterology – volume: 19 start-page: 275 year: 2019 end-page: 286 ident: bib5 article-title: Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomized, placebo controlled, phase 2 trial publication-title: Lancet Infect Dis – year: 2023 ident: bib25 article-title: A 3-year course of bulevirtide monotherapy may cure Hdv infection in cirrhotics publication-title: J Hepatol – volume: 70 start-page: 1008 year: 2019 end-page: 1015 ident: bib12 article-title: Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy publication-title: J Hepatol – year: 2013 ident: bib16 article-title: Collaborative study to establish a World Health Organization international standard for hepatitis D virus RNA for nucleic acid amplification technique (NAT)-based assays – volume: 78 start-page: S56 year: 2023 end-page: S57 ident: bib23 article-title: HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort publication-title: J Hepatol – volume: 73 start-page: 523 year: 2020 end-page: 532 ident: bib1 article-title: The global prevalence of hepatitis D virus infection: systematic review and meta-analysis publication-title: J Hepatol – volume: 56 year: 2024 ident: bib28 article-title: Burden of hepatitis D virus infection in Italy: interim results from a prospective multicentre nationwide study publication-title: Dig Liv Dis – volume: 67 start-page: 370 year: 2017 end-page: 398 ident: bib6 article-title: EASL clinical practice guidelines on the management of hepatitis B virus infection publication-title: J Hepatol – volume: 70 start-page: 1782 year: 2021 end-page: 1794 ident: bib18 article-title: Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease publication-title: Gut – volume: 9 year: 2014 ident: bib8 article-title: High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with Chronic Hepatitis Delta publication-title: PLoS One – volume: 78 start-page: S380 year: 2023 end-page: S381 ident: bib19 article-title: Evaluation of EurobioPlex EBX-071, a new commercial kit for HDV viral load quantification publication-title: Hepatology – volume: 5 year: 2023 ident: bib26 article-title: Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression publication-title: JHEP Rep – volume: 72 start-page: 539 year: 2020 end-page: 557 ident: bib11 article-title: 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B—report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference publication-title: J Hepatol – volume: 13 start-page: 2342 year: 2015 end-page: 2349.e1-2 ident: bib9 article-title: Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome publication-title: Clin Gastroenterol Hepatol – volume: 60 start-page: 87 year: 2014 end-page: 97 ident: bib27 article-title: Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta publication-title: Hepatology – volume: 64 start-page: 1483 year: 2016 end-page: 1494 ident: bib22 article-title: First international external quality assessment for hepatitis delta virus RNA quantification in plasma publication-title: Hepatology – volume: 81 start-page: 637 issue: 2 year: 2025 ident: 10.1016/j.jhepr.2024.101299_bib15 article-title: HDV RNA assays: performance characteristic, clinical utility, and challenges publication-title: Hepatology doi: 10.1097/HEP.0000000000000584 – volume: 221 start-page: 1677 year: 2020 ident: 10.1016/j.jhepr.2024.101299_bib2 article-title: Estimating the global prevalence, disease progression, and clinical outcome of Hepatitis Delta Virus infection publication-title: J Infect Dis doi: 10.1093/infdis/jiz633 – volume: 67 start-page: 370 year: 2017 ident: 10.1016/j.jhepr.2024.101299_bib6 article-title: EASL clinical practice guidelines on the management of hepatitis B virus infection publication-title: J Hepatol doi: 10.1016/j.jhep.2017.03.021 – volume: 5 year: 2023 ident: 10.1016/j.jhepr.2024.101299_bib26 article-title: Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression publication-title: JHEP Rep – volume: 78 start-page: S380 year: 2023 ident: 10.1016/j.jhepr.2024.101299_bib19 article-title: Evaluation of EurobioPlex EBX-071, a new commercial kit for HDV viral load quantification publication-title: Hepatology – volume: 73 start-page: 523 year: 2020 ident: 10.1016/j.jhepr.2024.101299_bib1 article-title: The global prevalence of hepatitis D virus infection: systematic review and meta-analysis publication-title: J Hepatol doi: 10.1016/j.jhep.2020.04.008 – volume: 70 start-page: 1782 year: 2021 ident: 10.1016/j.jhepr.2024.101299_bib18 article-title: Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease publication-title: Gut doi: 10.1136/gutjnl-2020-323888 – volume: 9 year: 2014 ident: 10.1016/j.jhepr.2024.101299_bib8 article-title: High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with Chronic Hepatitis Delta publication-title: PLoS One doi: 10.1371/journal.pone.0092062 – volume: 13 start-page: 2342 year: 2015 ident: 10.1016/j.jhepr.2024.101299_bib9 article-title: Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2015.05.029 – volume: 64 start-page: 1483 year: 2016 ident: 10.1016/j.jhepr.2024.101299_bib22 article-title: First international external quality assessment for hepatitis delta virus RNA quantification in plasma publication-title: Hepatology doi: 10.1002/hep.28772 – volume: 72 start-page: 539 year: 2020 ident: 10.1016/j.jhepr.2024.101299_bib11 article-title: 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B—report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference publication-title: J Hepatol doi: 10.1016/j.jhep.2019.11.003 – volume: 72 start-page: 1177 year: 2020 ident: 10.1016/j.jhepr.2024.101299_bib10 article-title: Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes publication-title: Hepatology doi: 10.1002/hep.31214 – volume: 70 start-page: 1008 year: 2019 ident: 10.1016/j.jhepr.2024.101299_bib12 article-title: Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy publication-title: J Hepatol doi: 10.1016/j.jhep.2018.12.022 – volume: 391 start-page: 133 year: 2024 ident: 10.1016/j.jhepr.2024.101299_bib29 article-title: Bulevirtide combined with pegylated interferon for chronic hepatitis D publication-title: N Engl J Med doi: 10.1056/NEJMoa2314134 – volume: 3 year: 2021 ident: 10.1016/j.jhepr.2024.101299_bib17 article-title: Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system publication-title: JHEP Rep – volume: 117 start-page: 161 year: 1999 ident: 10.1016/j.jhepr.2024.101299_bib4 article-title: Changing pattern of chronic hepatitis D in Southern Europe publication-title: Gastroenterology doi: 10.1016/S0016-5085(99)70563-9 – volume: 19 start-page: 275 year: 2019 ident: 10.1016/j.jhepr.2024.101299_bib5 article-title: Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomized, placebo controlled, phase 2 trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(18)30663-7 – year: 2013 ident: 10.1016/j.jhepr.2024.101299_bib16 – volume: 76 start-page: S26 year: 2022 ident: 10.1016/j.jhepr.2024.101299_bib24 article-title: Bulevirtide, with or without PEG-Interferon, in HDV infected patients in a real-life setting. Two years results from the French multicenter early access program publication-title: Hepatology – volume: 389 start-page: 22 year: 2023 ident: 10.1016/j.jhepr.2024.101299_bib20 article-title: A phase 3, randomized trial of bulevirtide in chronic hepatitis D publication-title: N Engl J Med doi: 10.1056/NEJMoa2213429 – year: 2023 ident: 10.1016/j.jhepr.2024.101299_bib25 article-title: A 3-year course of bulevirtide monotherapy may cure Hdv infection in cirrhotics publication-title: J Hepatol doi: 10.1016/j.jhep.2022.12.023 – volume: 155 start-page: 931 year: 1987 ident: 10.1016/j.jhepr.2024.101299_bib3 article-title: Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B publication-title: J Infect Dis doi: 10.1093/infdis/155.5.931 – volume: 56 year: 2024 ident: 10.1016/j.jhepr.2024.101299_bib28 article-title: Burden of hepatitis D virus infection in Italy: interim results from a prospective multicentre nationwide study publication-title: Dig Liv Dis doi: 10.1016/j.dld.2024.01.026 – volume: 142 year: 2021 ident: 10.1016/j.jhepr.2024.101299_bib13 article-title: Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: a European multicenter study publication-title: J Clin Virol doi: 10.1016/j.jcv.2021.104932 – volume: 24 start-page: 117 issue: 2 year: 2019 ident: 10.1016/j.jhepr.2024.101299_bib14 article-title: Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation publication-title: Antivir Ther doi: 10.3851/IMP3281 – volume: 60 start-page: 87 year: 2014 ident: 10.1016/j.jhepr.2024.101299_bib27 article-title: Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta publication-title: Hepatology doi: 10.1002/hep.27102 – volume: 78 start-page: S56 year: 2023 ident: 10.1016/j.jhepr.2024.101299_bib23 article-title: HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort publication-title: J Hepatol doi: 10.1016/S0168-8278(23)00520-2 – volume: 44 start-page: 831 year: 2024 ident: 10.1016/j.jhepr.2024.101299_bib21 article-title: Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods publication-title: Liver Int doi: 10.1111/liv.15795 |
| SSID | ssj0002794016 |
| Score | 2.2981763 |
| Snippet | Accurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability between assays exists.... Background & AimsAccurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability... Image 1 • Management of chronic hepatitis delta requires standardized tests for HDV RNA. • EurobioPlex reports 1 log IU/ml more and AltoStar 0.5 log IU/ml more... Background & Aims: Accurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 101299 |
| SubjectTerms | AltoStar Antiviral therapy Bulevirtide Chronic hepatitis delta EurobioPlex Gastroenterology and Hepatology HDV HDV RNA Nucleic acid PCR Robogene |
| Title | Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2589555924003033 https://www.clinicalkey.es/playcontent/1-s2.0-S2589555924003033 https://dx.doi.org/10.1016/j.jhepr.2024.101299 https://www.ncbi.nlm.nih.gov/pubmed/40051411 https://www.proquest.com/docview/3174820529 https://pubmed.ncbi.nlm.nih.gov/PMC11883403 https://doaj.org/article/267dc066f04349fda3e810f893a58c6e |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k14VEbiSETiV-xjKVQrpPYAFPVm-RW6K9VdyOb_M7aTZRcQvXBM4jjRzNjzjT3-BqHXPUz6xhBfe96Lmjnmagt6r0nn8sFFRfu0Dnl6Jhbn7OMFv9gp9ZVywgo9cBHcWyI678Av9g2jTPXe0CDbpgc3a7h0IqTZF3zeTjC1yttpCgIHMdMM5YSu1WVYJwZQwtIdktlef7mizNi_55H-RJy_J07ueKKTe-juBCHxUfn1--hWiA_Q7dNpk_whWh2X2oLxGy71oQcMyBSvASdfGbx4_xV_OjvC30dT8oSyavAyYjumo-bQqw91zj8PHpvo8Rjnq4mEdcBp9Tb19Aidn3z4cryop5IKteOSbmrVEKOYV9wKT4gyVlIqjJOt6SFKlhBbdJJz3wrfMatIkIBAFLW0cx0nRij6GB3E6xieIgyRIWHeSGYkaJhaK0UbfE9p4xpvCKvQm1m6el2YM_ScUrbSWRk6KUMXZVToXdLAtmmivc43wBj0ZAz6JmOoEJv1p-eTpTAXQkfLf3-7-9trYZjG86BbPRDd6M-ES8UhCEuZt-D8aYXE9s0JshQocvMnX83mpWFAp10aE8P1OGgAdAxgGSfQ5kkxt61QWKarb9sKyT1D3JPa_pO4vMyk4RBISsoa-ux_yPk5ukNSHeSci_cCHWx-jOElgLONPczj8DCvmv0E9kI3nw |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparing+methods+for+plasma+HDV+RNA+quantification+in+bulevirtide-treated+and+untreated+patients+with+HDV&rft.jtitle=JHEP+reports&rft.au=Anolli%2C+Maria+Paola&rft.au=Uceda+Renteria%2C+Sara&rft.au=Degasperi%2C+Elisabetta&rft.au=Facchetti%2C+Floriana&rft.date=2025-03-01&rft.pub=Elsevier+B.V&rft.issn=2589-5559&rft.eissn=2589-5559&rft.volume=7&rft.issue=3&rft_id=info:doi/10.1016%2Fj.jhepr.2024.101299&rft.externalDocID=S2589555924003033 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F25895559%2FS2589555925X00021%2Fcov150h.gif |